News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
387,763 Results
Type
Article (24010)
Company Profile (120)
Press Release (363625)
Multimedia
Podcasts (83)
Webinars (14)
Section
Business (114778)
Career Advice (966)
Deals (20628)
Drug Delivery (96)
Drug Development (51241)
Employer Resources (96)
FDA (8962)
Job Trends (8536)
News (199890)
Policy (18569)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (2)
Academia (1359)
Academic (1)
Accelerated approval (27)
Adcomms (15)
Allergies (118)
Alliances (30234)
ALS (111)
Alzheimer's disease (888)
Antibody-drug conjugate (ADC) (197)
Approvals (9283)
Artificial intelligence (348)
Autoimmune disease (119)
Automation (27)
Bankruptcy (183)
Best Places to Work (6333)
BIOSECURE Act (11)
Biosimilars (173)
Biotechnology (48)
Bladder cancer (77)
Brain cancer (48)
Breast cancer (343)
Cancer (2618)
Cardiovascular disease (299)
Career advice (846)
Career pathing (27)
CAR-T (127)
CDC (33)
Celiac Disease (2)
Cell therapy (361)
Cervical cancer (25)
Clinical research (45162)
Collaboration (1142)
Company closure (2)
Compensation (426)
Complete response letters (53)
COVID-19 (1593)
CRISPR (68)
C-suite (728)
Cystic fibrosis (77)
Data (4049)
Decentralized trials (1)
Denatured (26)
Depression (89)
Dermatology (42)
Diabetes (305)
Diagnostics (2786)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (30)
Drug discovery (189)
Drug pricing (143)
Drug shortages (28)
Duchenne muscular dystrophy (142)
Earnings (43420)
Editorial (44)
Employer branding (8)
Employer resources (89)
Events (54688)
Executive appointments (728)
FDA (10885)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (3)
Frontotemporal dementia (9)
Funding (852)
Gene editing (117)
Generative AI (32)
Gene therapy (347)
GLP-1 (700)
Government (2292)
Grass and pollen (6)
Guidances (233)
Healthcare (7976)
HIV (51)
Huntington's disease (23)
IgA nephropathy (59)
Immunology and inflammation (144)
Immuno-oncology (41)
Indications (118)
Infectious disease (1772)
Inflammatory bowel disease (131)
Inflation Reduction Act (9)
Influenza (67)
Intellectual property (143)
Interviews (149)
IPO (8195)
IRA (40)
Job creations (2425)
Job search strategy (734)
JPM (37)
Kidney cancer (13)
Labor market (56)
Layoffs (284)
Leadership (24)
Legal (4409)
Liver cancer (45)
Longevity (14)
Lung cancer (315)
Lymphoma (222)
Machine learning (25)
Management (35)
Manufacturing (643)
MASH (131)
Medical device (4183)
Medtech (4228)
Mergers & acquisitions (13110)
Metabolic disorders (871)
mRNA (98)
Multiple sclerosis (122)
NASH (20)
Neurodegenerative disease (172)
Neuropsychiatric disorders (55)
Neuroscience (1690)
Neurotech (1)
NextGen: Class of 2026 (3119)
Non-profit (2006)
Now hiring (26)
Obesity (417)
Opinion (189)
Ovarian cancer (109)
Pain (170)
Pancreatic cancer (110)
Parkinson's disease (175)
Partnered (21)
Patents (285)
Patient recruitment (283)
Peanut (31)
People (39111)
Pharmaceutical (63)
Pharmacy benefit managers (22)
Phase 1 (11695)
Phase 2 (19516)
Phase 3 (17021)
Pipeline (4589)
Policy (211)
Postmarket research (1821)
Preclinical (4720)
Press Release (48)
Prostate cancer (172)
Psychedelics (33)
Radiopharmaceuticals (189)
Rare diseases (623)
Real estate (3428)
Recruiting (36)
Regulatory (14800)
Reports (24)
Research institute (1316)
Resumes & cover letters (124)
Rett syndrome (11)
RNA editing (10)
RSV (48)
Schizophrenia (107)
Series A (165)
Series B (106)
Service/supplier (4)
Sickle cell disease (71)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (18)
Startups (2283)
State (2)
Stomach cancer (9)
Supply chain (71)
Tariffs (76)
The Weekly (55)
Vaccines (607)
Venture capital (62)
Weight loss (272)
Women's health (65)
Worklife (11)
Date
Last 7 days (353)
Last 30 days (1593)
Last 365 days (14792)
2026 (6296)
2025 (15127)
2024 (17684)
2023 (20082)
2022 (27230)
2021 (29113)
2020 (27971)
2019 (24070)
2018 (18623)
2017 (19167)
2016 (18476)
2015 (21949)
2014 (16755)
2013 (13797)
2012 (14962)
2011 (15671)
2010 (14042)
Location
Africa (475)
Alabama (27)
Alaska (4)
Arizona (134)
Arkansas (5)
Asia (27782)
Australia (4181)
California (5619)
Canada (2119)
China (891)
Colorado (231)
Connecticut (215)
Delaware (226)
Europe (60162)
Florida (1021)
Georgia (186)
Hawaii (1)
Idaho (25)
Illinois (607)
India (75)
Indiana (368)
Iowa (4)
Japan (402)
Kansas (88)
Kentucky (29)
Louisiana (19)
Maine (14)
Maryland (760)
Massachusetts (4242)
Michigan (101)
Minnesota (331)
Mississippi (1)
Missouri (64)
Montana (12)
Nebraska (13)
Nevada (46)
New Hampshire (19)
New Jersey (2082)
New Mexico (14)
New York (1672)
North Carolina (916)
North Dakota (2)
Northern California (2704)
Ohio (168)
Oklahoma (7)
Oregon (21)
Pennsylvania (1234)
Puerto Rico (18)
Rhode Island (20)
South America (716)
South Carolina (21)
Southern California (2389)
Tennessee (89)
Texas (815)
United States (21607)
Utah (118)
Virginia (225)
Washington D.C. (47)
Washington State (471)
West Virginia (1)
Wisconsin (63)
Wyoming (2)
387,763 Results for "simcere pharmaceutical group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
April 21, 2026
·
5 min read
Press Releases
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
April 1, 2026
·
4 min read
Inflammatory bowel disease
Boehringer Commits up to $1.26B in IBD Pact With China’s Simcere
The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory bowel diseases.
January 27, 2026
·
2 min read
·
Tristan Manalac
Press Releases
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
May 4, 2026
·
5 min read
Antibody-drug conjugate (ADC)
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal
The deal gets NextCure the rights to Simcere’s novel ADC for solid tumors outside of China.
June 16, 2025
·
1 min read
·
Dan Samorodnitsky
Government
PhMRA’s long-standing leader Steve Ubl to leave lobby group by year-end
Industry leader Steve Ubl has served as PhRMA’s CEO for more than a decade, the longest tenure of any head of the trade group.
April 9, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Juvisé Pharmaceuticals Formally Approved the Appointments of Frédéric Mascha as Executive Chairman and Chairman of the Supervisory Committee and the Nomination of Renaud Sermondade as the Group’s New CEO
April 16, 2026
·
2 min read
Press Releases
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
April 29, 2026
·
15 min read
Press Releases
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
January 27, 2026
·
3 min read
Rare diseases
Rare Disease Groups Lobby for Regulatory Expediency as Makary Defends ‘Rigorous’ Approach
This week’s Capitol Hill meetings come on the heels of rejections of ultra-rare disease drugs developed by Biohaven and Saol Therapeutics. Physicians and patient groups implored the FDA to expedite these treatments.
February 27, 2026
·
6 min read
·
Heather McKenzie
1 of 38,777
Next
